TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) stock: key figures, P/E, revenue and dividend
Health Care · ISIN US8816242098
TEVA PHARMACEUTICAL INDUSTRIES LTD financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 17.26 bn USD |
| Gross profit | 8.94 bn USD |
| Operating income | 2.16 bn USD |
| EBIT | 2.15 bn USD |
| Net income | 1.41 bn USD |
| Diluted EPS – continuing operations | 1.21 USD |
Full history since 1985, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About TEVA PHARMACEUTICAL INDUSTRIES LTD
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
More stocks
- Veeva Systems (VEEV)
- Commerzbank (CBK.DE)
- Fujikura Ltd (5803.T)
- Ford Motor Company (F)
- Rockwell Automation (ROK)
- Toyota Tsusho Corp (8015.T)
- MS&AD Insurance Group Holdings Inc (8725.T)
- Fujitsu Ltd (6702.T)
- Block, Inc. (XYZ)
- Zijin Gold International Co Ltd (2259.HK)
- Everpure, Inc. (P)
- Xcel Energy (XEL)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.